- $59.08m
- $53.58m
- $2.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.26 | ||
| Price to Tang. Book | 10.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -61.57% | ||
| Return on Equity | -80.83% | ||
| Operating Margin | -344% | ||
Financial Summary
| Year End 31st Jan | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.37 | 0.94 | 1.42 | 2.08 | 2.09 | 2.21 | 14.09 | 53.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Directors
- Serguei Melnik CHM (49)
- Gareth Sheridan CEO (32)
- Gerald Goodman CFO (73)
- Alan Smith COO (55)
- Patrick Ryan CTO (35)
- Jeff Patrick CSO (50)
- Larry Dillaha OTH (56)
- Irina Gram-Contulescu DRC (34)
- Michael Myer DRC (36)
- Radu Bujoreanu IND (49)
- Steven Damon IND (64)
- Vsevolod Grigore IND (62)
- Mark Hamilton IND (36)
- Stefan Mancas IND (43)
- Last Annual
- January 31st, 2024
- Last Interim
- October 31st, 2024
- Incorporated
- January 4th, 2016
- Public Since
- June 20th, 2017
- No. of Shareholders
- 110
- No. of Employees
- 13
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 11,106,185
- Address
- 121 S Orange Ave Ste 1500, ORLANDO, 32801-3241
- Web
- https://nutriband.com/
- Phone
- +1 4073776695
- Auditors
- Sadler, Gibb & Associates, LLC
Upcoming Events for NTRB
Q2 2026 Nutriband Inc Earnings Release
Similar to NTRB
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Nutriband share price?
As of Today at 22:23 UTC, shares in Nutriband are trading at $5.32. This share price information is delayed by 15 minutes.
How has the Nutriband share price performed this year?
Shares in Nutriband last closed at $5.32 and the price had moved by +45.75% over the past 365 days. In terms of relative price strength the Nutriband share price has outperformed the S&P500 Index by +34.54% over the past year.
What are the analyst and broker recommendations for Nutriband?
The overall consensus recommendation for Nutriband is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Nutriband dividend yield?
Nutriband does not currently pay a dividend.
Does Nutriband pay a dividend?
Nutriband does not currently pay a dividend.
When does Nutriband next pay dividends?
Nutriband does not currently pay a dividend.
How do I buy Nutriband shares?
To buy shares in Nutriband you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nutriband?
As of the previous close price of $5.32, shares in Nutriband had a market capitalisation of $59.08m.
Where are Nutriband shares listed?
Here are the trading details for Nutriband:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NTRB
What kind of share is Nutriband?
Based on an overall assessment of its quality, value and momentum Nutriband is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nutriband share price forecast for 2025?
The analyst consensus target price for shares in Nutriband is $13.00. That is 144.36% above the last closing price of $5.32.
Analysts covering Nutriband currently have a consensus Earnings Per Share (EPS) forecast of -$0.60 for the next financial year.
Find out moreWhat is the trend in the Nutriband share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nutriband. Over the past six months, its share price has underperformed the S&P500 Index by -2.31%.
As of the last closing price of $5.32, shares in Nutriband were trading -8.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nutriband PE Ratio?
The Nutriband PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nutriband?
Nutriband's management team is headed by:
- Serguei Melnik - CHM
- Gareth Sheridan - CEO
- Gerald Goodman - CFO
- Alan Smith - COO
- Patrick Ryan - CTO
- Jeff Patrick - CSO
- Larry Dillaha - OTH
- Irina Gram-Contulescu - DRC
- Michael Myer - DRC
- Radu Bujoreanu - IND
- Steven Damon - IND
- Vsevolod Grigore - IND
- Mark Hamilton - IND
- Stefan Mancas - IND